Ind-Swift Laboratories Limited has announced the forfeiture of ₹19,66,25,000/- following the lapse of 65,00,000 fully convertible warrants. The pharmaceutical company informed BSE and NSE on March 1, 2026, that warrant holder Saral Incorporated VCC Sub Fund 1 failed to exercise the conversion option within the prescribed timeframe.

Warrant Details and Timeline

The warrants were originally allotted on August 30, 2024, through preferential allotment with a conversion period of 18 months. The deadline for exercising the warrants was February 28, 2026, after which the unconverted warrants automatically lapsed.

Warrant Exercise Summary

Out of the total 2,60,00,000 warrants issued, the majority were successfully converted while a significant portion held by one investor lapsed.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As per Regulation 169(3) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the upfront subscription amount of 25% of the issue price stands forfeited by the company.

Impact on Capital Structure

Ind-Swift Laboratories clarified that the lapse of warrants does not result in any change to the company's paid-up equity share capital. The forfeited amount will be retained by the company as per regulatory provisions. The successful exercise of 1,95,00,000 warrants indicates strong investor confidence in the majority of the allotment.

Ind-Swift Laboratories Limited has completed a significant preferential allotment of equity shares following the conversion of fully convertible warrants by promoter group entity Essix Biosciences Limited. The transaction has triggered comprehensive regulatory disclosure requirements under SEBI regulations.

Warrant Conversion and Allotment Details

The Preferential Issue Committee of the Board of Directors approved the allotment during their meeting held on February 24, 2026. The allotment involved the conversion of 51,00,000 fully convertible warrants into equity shares by Essix Biosciences Limited, originally allotted on August 30, 2024.

Regulatory Compliance and Disclosure

Essix Biosciences Limited, represented by Director Himanshu Jain, filed comprehensive disclosures under multiple SEBI regulations on February 26, 2026. The company submitted notifications under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Impact on Share Capital Structure

Following the completion of this preferential allotment, Ind-Swift Laboratories' capital structure has been significantly enhanced. The paid-up equity share capital increased from ₹81,61,15,580 to ₹86,71,15,580, representing an addition of ₹5.10 crores.

Promoter Group Structure

The disclosure reveals that Essix Biosciences Limited acts in concert with 19 persons acting in concert (PACs), including key individuals such as Nidhi Munjal, Meenakshi Mehta, Ravi Mehta, Neeta Munjal, Himanshu Jain, Sunita Jain, Gopal Munjal, Saurabh Munjal, and others from the promoter families.

Ind-Swift Laboratories informed both NSE and BSE about the substantial acquisition through official communications dated February 27, 2026, ensuring full regulatory compliance under applicable takeover and insider trading regulations. The preferential allotment was conducted in accordance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.